萬隆控股集團(00030.HK):雲南白藥向公司認購7.3億港元可換股債券
格隆匯10月15日丨萬隆控股集團(00030.HK)公佈,公司已於10月14日與雲南白藥集團訂立認購協議,據此,公司已發行(而云南白藥集團認購)本金總額為7.3億港元的可換股債券,認購價等於可換股債券的本金總額。
初步換股價每股換股股份0.258港元計算並假設由現在至全面轉換可換股債券日期止公司已發行股本並無其他變動,公司於可換股債券所隨附換股權獲全面行使時將配發及發行合共2,829,457,364股換股股份,相當於:(a)公司現有已發行股本約43.88%;及(b)公司經發行2,829,457,364股換股股份擴大後的已發行股本約30.50%。
據悉,換股價每股0.258港元,較股份於認購協議簽署日期在聯交所所報的收市價每股0.260港元折讓約0.77%。
認購事項所得款項淨額約為7.28億港元。公司擬將認購事項所得款項淨額用作工業大麻和CBD相關的業務發展、研發、投資、收購或其他相關應用和機遇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.